Cannabidiol: Swinging the Marijuana Pendulum From ‘Weed’ to Medication to Treat the Opioid Epidemic

Trends in Neurosciences

Volumn 40, Issue 3, 2017, Pages 124-127

  Hurd, Yasmin L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; MEDICAL CANNABIS; NALOXONE; OPIATE; PSYCHOTROPIC AGENT;

DRUG DEPENDENCE; EPIDEMIC; HEALTH CARE POLICY; HUMAN; NEUROANATOMY; NEUROBIOLOGY; NOTE; OPIATE ADDICTION; POLITICS; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SIGNAL TRANSDUCTION; SOCIAL ASPECT; SUBSTANCE USE; ANIMAL; OPIOID-RELATED DISORDERS; PATHOPHYSIOLOGY;

ANIMALS; CANNABIDIOL; EPIDEMICS; HEALTH POLICY; HUMANS; MEDICAL MARIJUANA; OPIOID-RELATED DISORDERS; PSYCHOTROPIC DRUGS;

EID: 85011301849     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2016.12.006     Document Type: Note

References (15)

1. 1 Office of the Surgeon General, Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health., 2016, U.S. Department of Health and Human Services (HHS), Office of the Surgeon General.
2. 2 Kim, J.H., et al. State medical marijuana laws and the prevalence of opioids detected among fatally injured drivers. Am. J. Public Health 106 (2016), 2032–2037.
3. 3 Katsidoni, V., et al. Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addict. Biol. 18 (2013), 286–296.
4. 4 Vann, R.E., et al. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol. Depend. 94 (2008), 191–198.
5. 5 Devinsky, O., et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 15 (2016), 270–278.
6. 6 Hess, E.J., et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia 57 (2016), 1617–1624.
7. 7 Blessing, E.M., Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12 (2015), 825–836.
8. 8 Parsons, L.H., Hurd, Y.L., Endocannabinoid signalling in reward and addiction. Nat. Rev. Neurosci. 16 (2015), 579–594.
9. 9 Mechoulam, R., Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat. Rev. Neurosci. 15 (2014), 757–764.
10. 10 Campos, A.C., et al. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol. Res. 112 (2016), 119–127.
11. 11 Hsiao, Y.T., et al. Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats. Neuropharmacology 62 (2012), 373–384.
12. 9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry 66 (2009), 95–105.
13. 13 Hine, B., et al. Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats. Res. Commun. Chem. Pathol. Pharmacol. 12 (1975), 185–188.
14. 14 Ren, Y., et al. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J. Neurosci. 29 (2009), 14764–14769.
15. 15 Hurd, Y.L., et al. Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics 12 (2015), 807–815.